OPKO Health (NASDAQ:OPK) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of OPKO Health (NASDAQ:OPK) from a sell rating to a hold rating in a research report report published on Tuesday morning.

A number of other equities analysts have also recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research note on Thursday, September 26th. Barrington Research restated an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a research report on Friday, November 8th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $3.00 price objective on shares of OPKO Health in a research note on Tuesday, September 17th.

OPKO Health Trading Down 2.0 %

NASDAQ OPK opened at $1.48 on Tuesday. The stock has a market capitalization of $1.01 billion, a P/E ratio of -7.79 and a beta of 1.63. The firm has a 50-day moving average price of $1.54 and a 200 day moving average price of $1.50. OPKO Health has a 52-week low of $0.86 and a 52-week high of $1.76. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30.

Insider Buying and Selling at OPKO Health

In other news, CEO Phillip Md Et Al Frost bought 100,000 shares of the business’s stock in a transaction that occurred on Thursday, November 14th. The stock was purchased at an average price of $1.62 per share, with a total value of $162,000.00. Following the purchase, the chief executive officer now owns 211,612,405 shares of the company’s stock, valued at $342,812,096.10. This trade represents a 0.05 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Insiders have acquired 1,304,255 shares of company stock valued at $2,024,605 over the last quarter. Corporate insiders own 47.26% of the company’s stock.

Institutional Investors Weigh In On OPKO Health

A number of hedge funds and other institutional investors have recently modified their holdings of the company. CIBC Asset Management Inc boosted its position in OPKO Health by 79.1% during the second quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 8,978 shares during the last quarter. FMR LLC boosted its holdings in shares of OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 11,089 shares during the last quarter. Orion Portfolio Solutions LLC acquired a new stake in shares of OPKO Health during the third quarter worth $45,000. Algert Global LLC purchased a new stake in shares of OPKO Health in the second quarter valued at $44,000. Finally, Private Advisor Group LLC increased its stake in OPKO Health by 242.7% in the third quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 25,000 shares during the last quarter. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.